ArticleChinese medicine2026
Chemical proteomics reveals sinomenine's anti-inflammatory mechanism through serum protein covalent modification.
Article in Chinese medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundCovalent protein modification by drugs or their reactive metabolites has emerged as an important mechanism underlying pharmacological activity. However, its contribution to the therapeutic effects of compounds derived from traditional Chinese medicine remains insufficiently characterized. Sinomenine (SIN), an active alkaloid from Sinomenium acutum, has long been utilized in managing inflammatory disorders, yet the molecular basis of its efficacy is not fully elucidated.
methodsA discovery-driven chemical proteomics approach was deployed to investigate the role of covalent protein modification in the action of SIN. Metabolite profiling and in vitro reactivity assays were initially conducted to evaluate the modification potential of SIN and its metabolites. Subsequently, in vivo serum proteomics analysis in rat was performed to map the covalent modification landscape. Enriched biological pathways were identified through bioinformatics analyses, and functional validation was executed using western blotting and enzymatic activity assays.
resultsResults demonstrated that SIN, along with its oxygenated and demethylated metabolites, could covalently modify cysteine and lysine residues on proteins via three distinct modification patterns. Serum proteomics analysis identified seven proteins modified by SIN in vivo. Pathway enrichment analysis revealed that these target proteins were predominantly involved in coagulation and complement pathways. Functional validation demonstrated that SIN treatment significantly suppressed the activation of the coagulation cascade, the kallikrein-kinin system (KKS), and the complement cascade.
conclusionsThis study provides evidence that covalent protein modification may contribute to the pharmacological effects of SIN by modulating coagulation and complement pathways, which are implicated in inflammatory regulation. The findings offer new mechanistic insights into SIN's action and underscore the utility of covalent proteomics as an effective strategy for uncovering the molecular mechanisms of bioactive compounds derived from traditional Chinese medicine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.